Pheno.AI
- Company typePrivate
- Founded2022
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Pheno.AI firmographics
Firmographics- Name
- Pheno.AI
- Legal name
- Pheno.AI
- Website
- https://pheno.ai
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Pheno.AI industry classification
Industry- Product category
- AI Health Prediction Analytics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Programming Services (7371)
- akta.pro primary industry
- Healthcare & Wellness Personalization (HDAAAGAI)
Keywords
Where Pheno.AI is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Markets served
Pheno.AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pheno.AI product offering
Product offeringCore offering
Pheno.AI develops and commercializes an AI-powered digital twin model that predicts diseases before symptoms emerge by analyzing multi-layered health data — including continuous glucose monitor data, gut microbiome, diet, physical activity, and genetic information — across 17 body systems. The technology is grounded in the Human Phenotype Project, a large-scale data initiative involving 30,000+ registered participants, and is being commercialized in partnership with the Weizmann Institute of Science.
Product overview
Pheno.AI is associated with the Human Phenotype Project (HPP), which gathers extensive medical data from individuals for predictive health analysis. The source webpage is a minimal contact page with no detailed product or service information available.
Differentiator
Problem solved
Functional benefit
Products and services
- AI-Powered Digital Twin Health Prediction Model
- Human Phenotype Project (HPP) Data
Quantifiable outcome
- Identifies early signs of diabetes that standard tests may miss
- +1 more outcomes
Companies that use Pheno.AI
Customer profileSegments2 records
Ideal customer profiles2 records
Pheno.AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Pheno.AI partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Weizmann Institute of SciencecoreWeizmann Institute of Science researchers developed the AI-powered digital twin model underlying Pheno.AI's technology. The project is based on the Human Phenotype Project that gathered extensive medical data from over 13,000 individuals. Pheno.AI appears to be commercializing this research technology. The partnership involves co-development of predictive health technology with findings published in Nature Medicine.
- Human Phenotype Project ParticipantscoreOver 30,000 registered participants contribute health data to the Human Phenotype Project, which forms the data foundation for Pheno.AI's digital twin model. These individuals provide multi-layered health data including wearable sensor data, genetic information, microbiome data, and continuous glucose monitoring data.
Scale indicators4 records
Recent moves4 records
Expansion highlights4 records
Pheno.AI competitors and assessment
Company assessmentDirect peers
- ZOE: ZOE runs a large-scale nutrition and metabolic health study combining CGM, microbiome, and dietary data with AI-driven personalized insights. It is the closest commercial analog to Pheno.AI's multi-omics, consumer-facing health prediction approach.
- Owkin: Owkin applies AI to multimodal clinical and biological data to predict disease outcomes and treatment response. It is a comparable health-AI platform leveraging large federated datasets.
- Insitro: Insitro applies machine learning to large phenotypic and multi-omics datasets for drug discovery and disease prediction. It shares Pheno.AI's foundational approach of combining AI with deep human phenotype data.
- Levels Health: Levels builds a CGM-centric metabolic health platform that uses continuous glucose data to predict and explain individual health responses. It overlaps directly with Pheno.AI's CGM-based disease prediction layer.
Broad incumbents
- Tempus Labs: Tempus is a leading AI-driven precision medicine company applying large-scale multi-modal data (genomics, clinical, imaging) to disease prediction and treatment. It is a broader incumbent targeting overlapping health-AI use cases.
- GRAIL: GRAIL uses large-scale genomic and clinical data plus AI for early multi-cancer detection. It is a relevant comparator for the 'predict disease before symptoms' use case that Pheno.AI pursues.
- Verily Life Sciences: An Alphabet-owned health-AI company building multi-omics platforms (e.g., Baseline study) and wearable-driven health prediction tools. It is a well-capitalized incumbent operating in overlapping territory.
Emerging players
- K Health: K Health applies AI to large patient datasets for personalized clinical predictions and virtual primary care. It is a comparable AI-driven predictive health player with a consumer/clinical hybrid model.
- BioAge Labs: BioAge uses AI on multi-omics and clinical datasets to discover therapeutics targeting aging biology. It shares Pheno.AI's biological-age-based predictive framing and multi-omics methodology.
- Sano Genetics: Sano combines genetic testing with longitudinal phenotype data and AI-driven insights for personalized health. It overlaps with the genetic and phenotype-prediction dimensions of Pheno.AI's model.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
Pheno.AI social profiles
Digital presencePheno.AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pheno.AI leadership team
Management profileNumber of profiles
Pheno.AI funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pheno.AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pheno.AI
What does Pheno.AI do?
Pheno.AI develops and commercializes an AI-powered digital twin model that predicts diseases before symptoms emerge by analyzing multi-layered health data — including continuous glucose monitor data, gut microbiome, diet, physical activity, and genetic information — across 17 body systems. The technology is grounded in the Human Phenotype Project, a large-scale data initiative involving 30,000+ registered participants, and is being commercialized in partnership with the Weizmann Institute of Science.
Is Pheno.AI a public or private company?
Pheno.AI is a private company. It is classified as unknown and is currently operating.
When was Pheno.AI founded?
Pheno.AI was founded in 2022. It employs 11 to 50 people.
Where is Pheno.AI based?
Pheno.AI is headquartered in Tel Aviv, Israel, in the Middle East region.
Who are Pheno.AI's main competitors?
Direct peers on record are ZOE, Owkin, Insitro and Levels Health. Broad incumbents are Tempus Labs, GRAIL and Verily Life Sciences. Emerging players are K Health, BioAge Labs and Sano Genetics.
Does Pheno.AI have an API?
No public API is recorded for Pheno.AI.
What industry is Pheno.AI in?
Pheno.AI's product category is AI Health Prediction Analytics. Its primary akta.pro industry code is HDAAAGAI, Healthcare & Wellness Personalization. Its NAICS code is 541714 and its SIC code is 7372.